💡 Researchers develop SNIPR001, a combination of engineered phages with antibacterial CRISPR–Cas arming that can potentially address challenges related to antibiotic resistance in immunocompromised patients.
📌 Translocation of gut bacteria, from the gastrointestinal tract is a frequent cause of bloodstream infections. Up to 65% of 𝑬. 𝒄𝒐𝒍𝒊 isolated as the causative pathogen from bloodstream infections in patients with hematological cancers undergoing hematopoietic stem cell transplantation were resistant to fluoroquinolones. Other clinical options are needed that would prevent infections in these vulnerable patients, especially fluoroquinolone-resistant 𝑬. 𝒄𝒐𝒍𝒊
🔍 To address the significant unmet medical need for new prophylactic agents in patients with hematological malignancies, researchers developed SNIPR001, this combines state-of-the-art phage screening which is a combination of four CRISPR–Cas-armed phages that specifically target a diverse spectrum of 𝑬. 𝒄𝒐𝒍𝒊 strains.
📌 Individualized combinations of narrow-spectrum antibiotics such as SNIPR001 may be used first-line rather than use in addition to broad-spectrum antibiotics such as fluoroquinolones.
🔴 Researchers in this study exemplifly a potentially significant therapeutic advance in the field of antimicrobials for high-risk patient populations. This also serves as a blueprint for narrow-spectrum therapies for other life-threatening antimicrobial-resistant pathogens in high-risk patient populations.
Link to the article: bit.ly/3C89Loi
Published On: /06/2023
